Compare National Beverage Corp. (FIZZ) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs IDEXX Laboratories, Inc. — how do they compare? National Beverage Corp. trades at $30.72 (market cap $2.89B), while IDEXX Laboratories, Inc. trades at $573.96 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 16× National Beverage Corp.'s market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| FIZZ | IDXX | |
|---|---|---|
Market Cap | $2.89B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $46.75 | $766.68 |
52-Week Low | $30.53 | $526.44 |
Enterprise Value | $2.60B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $30.60, down 1.42% on the day, with bearish technical signals dominating. The stock shows mixed fundamentals with strong profitability metrics including 37% gross margins and 34% ROE, but faces growth challenges as revenue has stagnated around $1.2B annually. Recent earnings have missed expectations in three of the last four quarters, while the company maintains dividend payments with a recent $3.25 special dividend declaration.
The outlook remains cautious given stalled revenue growth and bearish analyst sentiment with 50% sell ratings. While valuation appears reasonable at 15.7x P/E, competitive pressures in the sparkling water market and declining LaCroix volumes present significant headwinds. The stock's current technical weakness near support levels suggests continued pressure unless fundamental catalysts emerge.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
